Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Mallinckrodt
Baxter
Moodys
Harvard Business School

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,236,804

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,236,804 protect, and when does it expire?

Patent 8,236,804 protects VIIBRYD and is included in one NDA.

This patent has sixty patent family members in twenty-nine countries.

Summary for Patent: 8,236,804
Title:Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Abstract: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine- , crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
Inventor(s): Bathe; Andreas (Darmstadt, DE), Helfert; Bernd (Ober-Ramstadt, DE), Neuenfeld; Steffen (Messel, DE), Kniel; Heike (Heppenheim, DE), Bartels; Matthias (Darmstadt, DE), Rudolph; Susanne (Dieburg, DE), Bottcher; Henning (Darmstadt, DE)
Assignee: Merck Patentgesellschaft (Darmstadt, DE)
Application Number:13/100,948
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,236,804
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,236,804

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 RX Yes Yes   Start Trial   Start Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 RX Yes No   Start Trial   Start Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 RX Yes No   Start Trial   Start Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,236,804

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01113647Jun 19, 2001

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Mallinckrodt
Harvard Business School
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.